麗珠醫藥(01513.HK):重組新型冠狀病毒融合蛋白疫苗V-01被納入序貫加強免疫緊急使用
格隆匯9月2日丨麗珠醫藥(01513.HK)公吿,公司獲悉,根據《中華人民共和國疫苗管理法》第二十條有關規定,公司控股附屬公司珠海市麗珠單抗生物技術有限公司與中國科學院生物物理研究所合作研發的“重組新型冠狀病毒融合蛋白疫苗”(V-01)經國家衞生健康委員會提出建議,中國國家藥品監督管理局組織論證同意納入新型冠狀病毒防疫序貫加強免疫緊急使用。
V-01自2020年7月開始立項研發,是麗珠單抗與中科院合作研發的具有自主知識產權的創新型新冠重組蛋白疫苗。V-01於2021年年初獲藥監局批准進行臨牀試驗,適應症為預防新型冠狀病毒感染所致疾病(COVID-19)。
公司V-01被納入序貫加強免疫緊急使用,將進一步提升公司的核心競爭力,若後續被國家相關部門規模化採購使用,將對公司業績產生一定的積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.